FY2025 EPS Estimates for NeuroPace Lifted by HC Wainwright

NeuroPace, Inc. (NASDAQ:NPCE) – Research analysts at HC Wainwright lifted their FY2025 earnings estimates for shares of NeuroPace in a note issued to investors on Tuesday, January 27th. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.68) per share for the year, up from their prior estimate of ($0.76). HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. HC Wainwright also issued estimates for NeuroPace’s Q4 2025 earnings at ($0.10) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.85) EPS.

Several other research analysts have also weighed in on the stock. JPMorgan Chase & Co. lifted their price objective on shares of NeuroPace from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. UBS Group reissued a “buy” rating on shares of NeuroPace in a report on Wednesday, January 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price objective on shares of NeuroPace in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research note on Monday, December 29th. Finally, Leerink Partners reaffirmed an “outperform” rating and set a $19.00 price target on shares of NeuroPace in a research report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, NeuroPace has an average rating of “Moderate Buy” and an average target price of $18.67.

NeuroPace Price Performance

Shares of NPCE opened at $15.61 on Thursday. The stock has a market cap of $519.97 million, a P/E ratio of -20.54 and a beta of 1.85. NeuroPace has a 1 year low of $7.56 and a 1 year high of $18.98. The stock’s 50-day moving average price is $16.22 and its two-hundred day moving average price is $12.23. The company has a current ratio of 4.86, a quick ratio of 3.94 and a debt-to-equity ratio of 3.17.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.09. The business had revenue of $27.35 million for the quarter, compared to analyst estimates of $24.64 million. NeuroPace had a negative return on equity of 136.60% and a negative net margin of 25.28%.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Divisadero Street Capital Management LP raised its position in NeuroPace by 529.2% in the 2nd quarter. Divisadero Street Capital Management LP now owns 242,120 shares of the company’s stock valued at $2,697,000 after buying an additional 203,640 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of NeuroPace by 44.6% during the 2nd quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock worth $5,406,000 after acquiring an additional 149,595 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of NeuroPace by 12.6% in the third quarter. Armistice Capital LLC now owns 1,298,000 shares of the company’s stock valued at $13,382,000 after purchasing an additional 145,665 shares during the last quarter. Essex Investment Management Co. LLC lifted its position in shares of NeuroPace by 194.2% in the third quarter. Essex Investment Management Co. LLC now owns 216,722 shares of the company’s stock worth $2,234,000 after purchasing an additional 143,063 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its holdings in NeuroPace by 89.8% during the third quarter. Qube Research & Technologies Ltd now owns 213,773 shares of the company’s stock worth $2,204,000 after purchasing an additional 101,136 shares during the last quarter. 78.83% of the stock is owned by institutional investors and hedge funds.

NeuroPace Company Profile

NeuroPace, Inc is a medical device company based in Mountain View, California, that develops innovative neuromodulation systems for the treatment of neurological disorders. Founded in the late 1990s out of research at Stanford University, the company’s mission centers on delivering closed-loop, “smart” therapies that monitor and respond to electrical activity in the brain. In 2020, NeuroPace completed its initial public offering and now trades on the NASDAQ under the ticker NPCE.

The company’s flagship product, the RNS® System, is an implantable device designed for adults with medically refractory focal epilepsy.